DRDorothy L. Rosenthal

Dorothy L. Rosenthal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dorothy L. Rosenthal has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Alain P. Verhest

    From the Task Force on Computerized Screening Devices and Performance Assessment, Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial, Kamuela, Hawaii, U.S.A., June 5–10, 1997

    1 shared publication
  • Anne Peebles

    From the Task Force on Computerized Screening Devices and Performance Assessment, Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial, Kamuela, Hawaii, U.S.A., June 5–10, 1997

    1 shared publication
  • Bryan Knight

    Department of Anatomical Pathology, Southern IML Pathology, SONIC Laboratories, Wollongong, NSW, Australia

    1 shared publication
  • Christopher J. VandenBussche

    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland

    1 shared publication
  • Daniel F. I. Kurtycz

    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin

    1 shared publication
  • David C. Wilbur

    Department of Pathology Harvard Medical School Boston Massachusetts

    1 shared publication

Latest Publications

  • Open Access

    Should the BK polyomavirus cytopathic effect be best classified as atypical or benign in urine cytology specimens?

    by Derek B. Allison, Matthew T. Olson, Mohammed Lilo, Mingjuan L. Zhang, Dorothy L. Rosenthal, Christopher J. VandenBussche

    BACKGROUND According to The Paris System for Reporting Urinary Cytology (TPS), the category of atypical urothelial cells (AUC) should not be applied to specimens in which cellular changes can be entirely attributed to the polyoma (BK) virus cytopathic effect (CPE). Until recently, cases with BK CPE at The Johns Hopkins Hospital were categorized as atypical urothelial cells of uncertain significance (AUC-US), which is equivalent to the TPS AUC category. This study was performed to determine how significantly the rate of AUC-US specimens would decrease if specimens with only BK CPE were classified as benign. METHODS Two reviewers and 1 adjudicator re-evaluated urinary tract specimens to determine whether sufficient cytological atypia justified an AUC-US diagnosis independent of the presence of BK CPE. For patients with surgical follow-up, the rate of high-grade urothelial carcinoma (HGUC) on tissue biopsy was tracked over a 5-year period. RESULTS The reclassification rate of AUC-US cases with BK CPE as benign was 62.6%. The rate of subsequent HGUC was 6.0% for cases reclassified as benign and 10.0% for cases still classified as AUC-US. These rates were not significantly elevated in comparison with control cohorts among all-comers. However, for patients without a history of HGUC, the rate of HGUC on follow-up was significantly elevated in comparison with the rate for a benign control cohort and was similar to the rate for the AUC-US control cohort. CONCLUSIONS Reclassification as benign would have decreased the rate of AUC-US from 24.8% to 20.7% during the study year. However, the high rate of subsequent HGUC among nonsurveillance patients suggests that the reclassification of specimens with BK CPE in these patients may be inappropriate. Cancer Cytopathol 2016;124:436–42. © 2016 American Cancer Society.


  • Computerized Screening Devices and Performance Assessment: Development of a Policy Towards Automation

    by Peter H. Bartels, Marluce Bibbo, Martha L. Hutchinson, Thomas Gahm, Heinz K. Grohs, Elaine Gwi-Mak, Edward A. Kaufman, Raymond H. Kaufman, Bryan Kenyon Knight, Leopold G. Koss, et al.

    The extension of automation to the diagnostic assessment of clinical materials raises issues of professional responsibility, on the part of both the medical professional and designer of the device. The International Academy of Cytology (IAC) and other professional cytology societies should develop a policy towards automation in the diagnostic assessment of clinical cytologic materials. The following summarizes the discussion of the initial position statement at the International Expert Conference on Diagnostic Cytology Towards the 21st Century, Hawaii, June 1997. 1. The professional in charge of a clinical cytopathology laboratory continues to bear the ultimate medical responsibility for diagnostic decisions made at the facility, whether automated devices are involved or not. 2. The introduction of automated procedures into clinical cytology should under no circumstances lead to a lowering of standards of performance. A prime objective of any guidelines should be to ensure that an automated procedure, in principle, does not expose any patient to new risks, nor should it increase already-existing, inherent risks. 3. Automated devices should provide capabilities for the medical professional to conduct periodic tests of the appropriate performance of the device. 4. Supervisory personnel should continue visual quality control screening of a certain percentage of slides dismissed at primary screening as within normal limits (WNL), even when automated procedures are employed in the laboratory. 5. Specifications for the design of primary screening devices for the detection of cervical cancer issued by the IAC in 1984 were reaffirmed. 6. The setting of numeric performance criteria is the proper charge of regulatory agencies, which also have the power of enforcement. 7. Human expert verification of results represents the "gold standard" at this time. Performance characteristics of computerized cytology devices should be determined by adherence to defined and well-considered protocols. Manufacturers should not claim a new standard of care; this is the responsibility of the medical community and professional groups. 8. Cytology professionals should support the development of procedures that bring about an improvement in diagnostic decision making. Advances in technology should be adopted if they can help solve problems in clinical cytology. The introduction of automated procedures into diagnostic decision making should take place strictly under the supervision and with the active participation and critical evaluation by the professional cytology community. Guidelines should be developed for the communication of technical information about the performance of automated screening devices by the IAC to governmental agencies and national societies. Also, guidelines are necessary for the official communication of IAC concerns to industry, medicolegal entities and the media. Procedures and guidelines for the evaluation of studies pertaining to the performance of automated devices, performance metrics and definitions for evaluation criteria should be established.